Drug intelligence / Profile preview

hypothemycin

Development stage
Preclinical
Modality
RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
01

Overview

Hypothemycin is a natural product macrolide and resorcylic acid lactone polyketide originally isolated from fungi such as Hypomyces subiculosus, Setophoma terrestris, and H. tricothecoides[2][3][4]. It exhibits potent anticancer, antifungal, and anti-parasitic activities[2][4]. Mechanistically, hypothemycin acts as a covalent inhibitor of a subset of protein kinases—especially those with a cysteine residue preceding the catalytic DXG motif—including mitogen-activated protein kinase (MAPK/ERK pathway), MEK1/2, ERK1/2, PDGFR, VEGFR2, FLT3, and others[5][7][8]. It inhibits cell survival in various cancer cells (e.g., melanoma and colon cancer), suppresses growth of Trypanosoma brucei (the causative agent of sleeping sickness) in vitro and in vivo mouse models[4][5], disrupts cell wall/endosomal function in certain fungi[4], and suppresses tumor necrosis factor-alpha production by destabilizing TNF-alpha mRNA via inhibition of p38 MAPK and ERK phosphorylation pathways[8]. Hypothemycin has not been approved for clinical use but is used experimentally to probe kinase biology.

Other names
aigialomycin A
02

Targets

MAPK3 (Mitogen-activated protein kinase 1)MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)PDGFRA (Platelet-derived growth factor receptor alpha)VEGFR2 (Vascular endothelial growth factor receptor 2)MAPK14 (p38 mitogen-activated protein kinase alpha)

Beyond the preview

Go deeper on hypothemycin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on hypothemycin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call